Scholarlink

<p>T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月27日

查看全文
  • Luciano J. Costa,
  • Rahul Banerjee,
  • Hira Mian,
  • Katja Weisel,
  • Susan Bal,
  • Benjamin A. Derman,
  • Maung M. Htut,
  • Chandramouli Nagarajan,
  • Cesar Rodriguez,
  • Joshua Richter,
  • Matthew J. Frigault,
  • Jing C. Ye,
  • Niels W. C. J. van de Donk,
  • Peter M. Voorhees,
  • Benjamin Puliafito,
  • Nizar Bahlis,
  • Rakesh Popat,
  • Wee Joo Chng,
  • P. Joy Ho,
  • Gurbakhash Kaur,
  • Prashant Kapoor,
  • Juan Du,
  • Fredrik Schjesvold,
  • Jesus Berdeja,
  • Hermann Einsele,
  • Adam D. Cohen,
  • Joseph Mikhael,
  • Yelak Biru,
  • S. Vincent Rajkumar,
  • Yi Lin,
  • Thomas G. Martin,
  • Ajai Chari

摘要

T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.